direct factor Xa inhibitors

Browse trials
Matrix  

Edoxabanatrial fibrillation, in all type of patients vs warfarin standard dose

Gastrointestinal major bleeding by 23% adverse event

Lifethreatening major bleeding by 49% suggested

major or clinically relevant non-major bleeding by 14% suggested

Major bleeding by 20% suggested

Haemmorhagic stroke by 53% suggested

Fatal bleeding by 45% suggested

Cardiovascular death by 14% suggested

Edoxaban vs enoxaparin (short duration)

major VTE (fatal and non fatal DVT,PE) by 66% suggested

asymptomatic DVT by 62% suggested

distal DVT by 64% suggested

Dabigatranacute coronary syndrome, in all type of patients vs placebo

all NS

Apixabanacute coronary syndrome, in all type of patients vs placebo

major or minor bleeding by 174% adverse event

any bleedings by 121% adverse event

major or clinically relevant non-major bleeding by 139% adverse event

Major bleeding by 153% adverse event

Apixabanatrial fibrillation, in all type of patients vs warfarin standard dose

thrombo-embolic event (cerebral or systemic) by 20% fully demonstrated

Major bleeding by 30% fully demonstrated

All cause death by 11% fully demonstrated

major or clinically relevant non-major bleeding by 30% suggested

Haemmorhagic stroke by 49% suggested

stroke (fatal and non fatal) by 21% suggested

Apixaban vs aspirin

thrombo-embolic event (cerebral or systemic) by 54% suggested

ischemic stroke by 63% suggested

stroke (fatal and non fatal) by 54% suggested

Apixaban vs enoxaparin

major VTE (fatal and non fatal DVT,PE) by 60% suggested

Deep vein thrombosis by 68% suggested

total VTE and all-cause mortality by 64% suggested

asymptomatic DVT by 67% suggested

proximal DVT by 65% suggested

Apixaban vs enoxaparin (europe regimen)

major VTE (fatal and non fatal DVT,PE) by 50% suggested

Deep vein thrombosis by 40% suggested

total VTE and all-cause mortality by 38% suggested

proximal DVT by 65% suggested

Apixaban vs enoxaparin (US regimen)

major or clinically relevant non-major bleeding by 33% suggested

Otamixabanacute coronary syndrome, in all type of patients vs unfractionated heparin

all NS

Rivaroxabanacute coronary syndrome, in all type of patients vs placebo

major or minor bleeding by 75% adverse event

any bleedings by 100% adverse event

major or clinically relevant non-major bleeding by 106% adverse event

Major bleeding by 304% adverse event

cardiovascular events by 37% suggested

Cardiovascular death by 49% suggested

myocardial infarction (fatal and non fatal) by 33% suggested

All cause death by 48% suggested

Rivaroxabanatrial fibrillation, in all type of patients vs warfarin standard dose

Gastrointestinal major bleeding by 46% adverse event

Lifethreatening major bleeding by 31% suggested

Haemmorhagic stroke by 42% suggested

Fatal bleeding by 50% suggested

Rivaroxabancardiovascular prevention, in secondary prevention vs aspirin

Cardiovascular death by 7700% suggested

stroke (fatal and non fatal) by 5700% suggested

ischemic stroke by 5000% suggested

All cause death by 8100% suggested

Fatal stroke by 7700% suggested

Rivaroxabanthrombosis prevention, in all type of patients vs enoxaparin

major VTE (fatal and non fatal DVT,PE) by 88% suggested

Deep vein thrombosis by 77% suggested

total VTE and all-cause mortality by 70% suggested

proximal DVT by 97% suggested

Rivaroxaban vs enoxaparin (europe regimen)

major VTE (fatal and non fatal DVT,PE) by 62% suggested

Deep vein thrombosis by 47% suggested

total VTE and all-cause mortality by 49% suggested

distal DVT by 47% suggested

Symptomatic venous thromboembolism (DVT, PE) by 66% suggested

Rivaroxaban vs enoxaparin (short duration)

major VTE (fatal and non fatal DVT,PE) by 88% suggested

Deep vein thrombosis by 74% suggested

total VTE and all-cause mortality by 73% suggested

distal DVT by 66% suggested

proximal DVT by 81% suggested

Symptomatic venous thromboembolism (DVT, PE) by 80% suggested

Rivaroxaban vs enoxaparin (US regimen)

total VTE and all-cause mortality by 31% suggested

proximal DVT by 77% suggested

Ximelagatranacute coronary syndrome, in all type of patients vs placebo

all NS

Ximelagatranvenous thrombosis, in all type of patients vs discontinuation

VTE by 76% suggested